<!DOCTYPE html>
<html lang="en-us">
  <head>
    <meta charset="utf-8">
    <meta name="viewport" content="width=device-width, initial-scale=1">
    
    <title>Posts | Fallingstar Daily R</title>
    <link rel="stylesheet" href="/css/style.css" />
    <link rel="stylesheet" href="/css/fonts.css" />
    <link href="//cdn.bootcss.com/highlight.js/9.12.0/styles/github.min.css" rel="stylesheet">

  </head>

  <body>
    <nav class="header">
      <div class="banner">
<a href="/" class="text">
&Ffr;&Afr;&Lfr;&Lfr;&Ifr;&Nfr;&Gfr;&Sfr;&Tfr;&Afr;&Rfr; &Dfr;&Afr;&Ifr;&Lfr;&Yfr; &Rfr;
</a>
</div>

      <div class="head-meta">
      
        <span>Posts</span>
        <span>2024-04-06</span>
      
      </div>
    </nav>


<div class="container">
<main class="list">

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38581289/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240406181050&amp;v=2.18.0.post9&#43;e462414">Learnings from phosphatidylinositol 3-kinase inhibitors in lymphoma-Moving to a model where less can be more</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-06</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38581289-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240406181050-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    The role of Pi3K inhibitors in lymphoma is diminishing due to the adverse results from trials in indolent lymphoma, but is a one-size-fits-all approach to drug development penalising some lymphoma subtypes and the newer generation of Pi3K inhibitors? The report by Soumerai et al. of zandelisib with zanubrutinib in follicular and mantle cell lymphoma is an important addition to the data. Commentary on: Soumerai et al. Safety and efficacy of zandelisib plus zanubrutinib in previously &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38581389/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240406181050&amp;v=2.18.0.post9&#43;e462414">Effect of Empagliflozin on Heart Failure Outcomes After Acute Myocardial Infarction: Insights from the EMPACT-MI Trial</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-06</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38581389-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240406181050-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: In patients after acute myocardial infarction with left ventricular dysfunction or congestion, empagliflozin reduced the risk of heart &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38581410/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240406181050&amp;v=2.18.0.post9&#43;e462414">Adverse Events Reporting in Digital Interventions Evaluations for Psychosis: A Systematic Literature Search and Individual Level Content Analysis of Adverse Event Reports</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-06</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38581410-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240406181050-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: The results support the safety of DHIs, but AEs must be routinely monitored and evaluated according to best practice. Individual-level analyses of AEs have merit to understand safety in this emerging field. Recommendations for best practice reporting in future studies are &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38581422/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1x5bM_TNL8gjogAcnslpo2s2PbDe-61JVM2h9yowOYSiZ7Dkrt&amp;fc=20220919211934&amp;ff=20240406181011&amp;v=2.18.0.post9&#43;e462414">HyGAnno: hybrid graph neural network-based cell type annotation for single-cell ATAC sequencing data</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-06</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38581422-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1x5bm-tnl8gjogacnslpo2s2pbde-61jvm2h9yowoysiz7dkrt-fc-20220919211934-ff-20240406181011-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Reliable cell type annotations are crucial for investigating cellular heterogeneity in single-cell omics data. Although various computational approaches have been proposed for single-cell RNA sequencing (scRNA-seq) annotation, high-quality cell labels are still lacking in single-cell sequencing assay for transposase-accessible chromatin (scATAC-seq) data, because of extreme sparsity and inconsistent chromatin accessibility between datasets. Here, we present a novel automated cell &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38581519/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240406181050&amp;v=2.18.0.post9&#43;e462414">Cardio-renovascular health: The new guidelines</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-06</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38581519-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240406181050-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    No &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1251560221/O8so5fhki">Ramy在HBO Max上不久前播出了一个standup（脱口秀），里面说他最怕的人就是那些在家里挂一张美国国旗的。感同身受。别说家里面挂一张美国国旗了，就是那些在车上...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-06</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1251560221-o8so5fhki/">
    
    
    
    
    
      
    
    Ramy在HBO Max上不久前播出了一个standup（脱口秀），里面说他最怕的人就是那些在家里挂一张美国国旗的。感同身受。别说家里面挂一张美国国旗了，就是那些在车上贴个美国国旗的也挺可怕的，尤其是pickup，弄不好toolbox里就是一把AR-15。 <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/3825863518/O8ukjmojV">来一杯桑葚薄荷拿铁 [图片]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-06</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-3825863518-o8ukjmojv/">
    
    
    
    
    
      
    
    来一杯桑葚薄荷拿铁 <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5286768287/O8uAKly9w">长大后我成为了你</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-06</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5286768287-o8uakly9w/">
    
    
    
    
    
      
    
    长大后我成为了你  &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5286768287/O8vDBihho">转发微博 - 转发 @山下美月教会:&amp;ensp;山下美月 今天4月6日(土)23:00～、NHK「Venue101」中乃木坂46将会出演🪩✨今天将会穿着西部风格的新服装进行表演！🤍...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-06</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5286768287-o8vdbihho/">
    
    
    
    
    
      
    
    转发微博<!-- raw HTML omitted --><!-- raw HTML omitted --> - 转发 <!-- raw HTML omitted -->@山下美月教会<!-- raw HTML omitted -->: <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->山下美月<!-- raw HTML omitted --><!-- raw HTML omitted --> <!-- raw HTML omitted -->今天4月6日(土)23:00～、NHK「Venue101」中乃木坂46将会出演🪩✨<!-- raw HTML omitted --><!-- raw HTML omitted -->今天将会穿着西部风格的新服装进行表演！ &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5286768287/O8wIMxwb3">谁发明的钉耙子刘海[举车] - 转发 @顶筆TEN使:&amp;ensp;久保史绪里#shiorigram# .GEKI×CINE『天号星』今天上映了…！！我初次有幸参加的，剧团☆新感线桑的舞台剧...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-06</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5286768287-o8wimxwb3/">
    
    
    
    
    
      
    
    谁发明的钉耙子刘海<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> - 转发 <!-- raw HTML omitted -->@顶筆TEN使<!-- raw HTML omitted -->: <!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;img style=&ldquo;width: 1rem;height: 1rem&rdquo; src=&ldquo;<a href="https://n.sinaimg.cn/photo/5213b46e/">https://n.sinaimg.cn/photo/5213b46e/</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5286768287/O8yAr3SU4">不知道在干什么于是莫名其妙通宵了（</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-06</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5286768287-o8yar3su4/">
    
    
    
    
    
      
    
    不知道在干什么<!-- raw HTML omitted -->于是莫名其妙通宵了（  &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5402554084/O8shJvGws">就小孩子嘛！毫無違和感！[哈哈][哇] - 转发 @乌冬很怂不进击:&amp;ensp;via.Tiktok 乌冬很怂不进击的微博视频</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-06</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5402554084-o8shjvgws/">
    
    
    
    
    
      
    
    就小孩子嘛！毫無違和感！<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> - 转发 <!-- raw HTML omitted -->@乌冬很怂不进击<!-- raw HTML omitted -->: via.Tiktok <!-- raw HTML omitted -->&lt;span &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5402554084/O8skSDKti">轉發微博 - 转发 @乌冬很怂不进击:&amp;ensp;生田绘梨花 #生田绘梨花# via.Tiktok 乌冬很怂不进击的微博视频</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-06</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5402554084-o8sksdkti/">
    
    
    
    
    
      
    
    轉發微博<!-- raw HTML omitted --><!-- raw HTML omitted --> - 转发 <!-- raw HTML omitted -->@乌冬很怂不进击<!-- raw HTML omitted -->: <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->生田绘梨花<!-- raw HTML omitted --><!-- raw HTML omitted --> &lt;a href=&ldquo;<a href="https://m.weibo.cn/search?containerid=231522type%3D1%26t%3D10%26q%3D%23%E7%94%9F%E7%94%B0%E7%25">https://m.weibo.cn/search?containerid=231522type%3D1%26t%3D10%26q%3D%23%E7%94%9F%E7%94%B0%E7%</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5402554084/O8tWmcM6i">團寵 - 转发 @顶筆TEN使:&amp;ensp;久保史绪里#shiorigram# 东京也好大阪也好舞台左侧和右侧的后台都各有一个我的团扇给大家用…工作人员和其他演员们都来了夏巡…圣...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-06</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5402554084-o8twmcm6i/">
    
    
    
    
    
      
    
    團寵<!-- raw HTML omitted --><!-- raw HTML omitted --> - 转发 <!-- raw HTML omitted -->@顶筆TEN使<!-- raw HTML omitted -->: <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->久保史绪里<!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;a href=&ldquo;<a href="https://m.weibo.cn/search?containerid=231522type%3D1%26t">https://m.weibo.cn/search?containerid=231522type%3D1%26t</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5878312122/O8wqSkuiJ">棋手战鹰←这个家伙啥时候生日来着？</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-06</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5878312122-o8wqskuij/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->棋手战鹰<!-- raw HTML omitted --><!-- raw HTML omitted -->←这个家伙啥时候生日来着？  &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5878312122/O8wt24kov">发布了头条文章：《怪童丸：木谷实的乘胜追击——日本围棋百大奠基人005》 #围棋# 围棋 怪童丸：木谷实的乘胜追击——日本围棋百大奠基人005 [图片]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-06</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5878312122-o8wt24kov/">
    
    
    
    
    
      
    
    发布了头条文章：《怪童丸：木谷实的乘胜追击——日本围棋百大奠基人005》 <!-- raw HTML omitted --><!-- raw HTML omitted -->#围棋#<!-- raw HTML omitted --><!-- raw HTML omitted --> <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->围棋<!-- raw HTML omitted --><!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5878312122/O8wzoEIxg">发布了头条文章：《芝野虎丸朝着“毕业”大步迈进》 #围棋# 围棋 芝野虎丸朝着“毕业”大步迈进 [图片]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-06</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5878312122-o8wzoeixg/">
    
    
    
    
    
      
    
    发布了头条文章：《芝野虎丸朝着“毕业”大步迈进》 <!-- raw HTML omitted --><!-- raw HTML omitted -->#围棋#<!-- raw HTML omitted --><!-- raw HTML omitted --> <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->围棋<!-- raw HTML omitted --><!-- raw HTML omitted --> &lt;a &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/6015489225/O8s1ubSQR">久保史绪里 - 转发 @YodaChannel:&amp;ensp;与田祐希 #与田祐希# 2024.04.05 11:48 YodaChannel的微博视频</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-06</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-6015489225-o8s1ubsqr/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->久保史绪里<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> - 转发 <!-- raw HTML omitted -->@YodaChannel<!-- raw HTML omitted -->: &lt;a href=&ldquo;<a href="https://m.weibo.cn/p/index?extparam=%E4%B8%8E%E7%94%B0%E7%A5%90%E5%B8%8C&amp;amp;containerid=10080814f44">https://m.weibo.cn/p/index?extparam=%E4%B8%8E%E7%94%B0%E7%A5%90%E5%B8%8C&amp;amp;containerid=10080814f44</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/6015489225/O8svU7hbx">久保史绪里#久保史绪里手机博# 2024.04.05 09:42(补)「呜呼呼」早上好〜昨晚是要反省的一夜…在完成必须要做的事情前就睡着了…睡着了…希望今天能弥补过来…这...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-06</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-6015489225-o8svu7hbx/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->久保史绪里<!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;a href=&ldquo;<a href="https://m.weibo.cn/search?containerid=231522type%3D1%26t%3D10%26q%3D%23%E4%B9%85%E4%BF%9D%E5%8F%B2%E7%BB%AA%E9%87%8C%E6%89%8B%E6%9C%BA%E5%8D%25">https://m.weibo.cn/search?containerid=231522type%3D1%26t%3D10%26q%3D%23%E4%B9%85%E4%BF%9D%E5%8F%B2%E7%BB%AA%E9%87%8C%E6%89%8B%E6%9C%BA%E5%8D%</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/6015489225/O8sx3ETgU">久保史绪里#shiorigram# .GEKI×CINE『天号星』今天上映了…！！我初次有幸参加的，剧团☆新感线桑的舞台剧。是我难以忘怀的经验。我也打算在电影院，再次感受那...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-06</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-6015489225-o8sx3etgu/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->久保史绪里<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->#shiorigram# &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/6015489225/O8sxDhthc">久保史绪里#久保史绪里手机博# 2024.04.06 13:09「梦想和现实」早上好〜心里平和的日子真是美好呢～现在的心情是想去海边这么说的同时，必须要做的事情就在我眼...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-06</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-6015489225-o8sxdhthc/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->久保史绪里<!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;a href=&ldquo;<a href="https://m.weibo.cn/search?containerid=231522type%3D1%26t%3D10%26q%3D%23%E4%B9%85%E4%BF%9D%E5%8F%B2%E7%BB%AA%E9%87%8C%E6%89%8B%E6%9C%BA%E5%8D">https://m.weibo.cn/search?containerid=231522type%3D1%26t%3D10%26q%3D%23%E4%B9%85%E4%BF%9D%E5%8F%B2%E7%BB%AA%E9%87%8C%E6%89%8B%E6%9C%BA%E5%8D</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/6015489225/O8sxhdl62">久保史绪里#shiorigram# 东京也好大阪也好舞台左侧和右侧的后台都各有一个我的团扇给大家用…工作人员和其他演员们都来了夏巡…圣子桑就算在休息室也一直都在使...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-06</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-6015489225-o8sxhdl62/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->久保史绪里<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;span &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/6015489225/O8sxScQrA">久保史绪里天號星 院线发布 媒体图 更新 [图片][图片][图片][图片][图片]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-06</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-6015489225-o8sxscqra/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->久保史绪里<!-- raw HTML omitted --><!-- raw HTML omitted -->天號星 院线发布 媒体图 更新 <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;img style=&quot;&quot; src=&ldquo;<a href="https://tvax3.sinaimg.cn/large/006z6nxLgy1ho">https://tvax3.sinaimg.cn/large/006z6nxLgy1ho</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/6015489225/O8sxwDwuZ">久保史绪里#久保史绪里手机博# 2024.04.05 22:06(补)「无题」这周感觉不知怎的，周三广播周四Nogiobi周五舞台见面会周六音乐节目每天都能够以不同的自己，触及到...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-06</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-6015489225-o8sxwdwuz/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->久保史绪里<!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;a href=&ldquo;<a href="https://m.weibo.cn/search?containerid=231522type%3D1%26t%3D10%26q%3D%23%E4%25B">https://m.weibo.cn/search?containerid=231522type%3D1%26t%3D10%26q%3D%23%E4%B</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38576222/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240405180803&amp;v=2.18.0.post9&#43;e462414">Biological Variation Estimates for Plasma Copeptin and Clinical Implications</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-05</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38576222-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240405180803-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: The availability of BV data allows for refined APS and associated II, and RCVs applicable as aids in the serial monitoring of patients with specific diseases such as heart failure. The BV estimates are only applicable in subjects who abstained from oral intake due to the rapid and marked effects of fluids on copeptin &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38576796/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240405180803&amp;v=2.18.0.post9&#43;e462414">Is there an immunological cross-reactivity of antibodies to the myelin oligodendrocyte glycoprotein and coronaviruses?</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-05</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38576796-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240405180803-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Recent reports indicated that myelin oligodendrocyte glycoprotein antibody-associated disease might be a rare complication after severe acute respiratory syndrome coronavirus 2 infection or vaccination. It is unclear whether this is an unspecific sequel of infection or vaccination or caused by possible immunological cross-reactivity of severe acute respiratory syndrome coronavirus 2 proteins and myelin oligodendrocyte glycoprotein. The aim of this study was therefore to elucidate whether &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38577107/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240405180803&amp;v=2.18.0.post9&#43;e462414">Disruption of CD47-SIRPα signaling restores inflammatory function in tumor-associated myeloid-derived suppressor cells</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-05</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38577107-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240405180803-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Myeloid-derived suppressor cells (MDSCs) are a heterogeneous immune population with diverse immunosuppressive functions in solid tumors. Here, we explored the role of the tumor microenvironment in regulating MDSC differentiation and immunosuppressive properties via signal-regulatory protein alpha (SIRPα)/CD47 signaling. In a murine melanoma model, we observed progressive increases in monocytic MDSCs and monocyte-derived dendritic cells that exhibited potent T cell-suppressive capabilities. &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38577494/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1Rkszs2HVZ2RHP33OibaNFew6VK-LzjJWTD4GwmLlk8B-wCceh&amp;fc=20220923065203&amp;ff=20240405180744&amp;v=2.18.0.post9&#43;e462414">Resolution of metastatic neck nodes associated with a periauricular cutaneous squamous cell carcinoma after intranodal injection of talimogene laherparepvec</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-05</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38577494-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1rkszs2hvz2rhp33oibanfew6vk-lzjjwtd4gwmllk8b-wcceh-fc-20220923065203-ff-20240405180744-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    No &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38577494/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1Rkszs2HVZ2RHP33OibaNFew6VK-LzjJWTD4GwmLlk8B-wCceh&amp;fc=20220923065203&amp;ff=20240406181021&amp;v=2.18.0.post9&#43;e462414">Resolution of metastatic neck nodes associated with a periauricular cutaneous squamous cell carcinoma after intranodal injection of talimogene laherparepvec</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-05</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38577494-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1rkszs2hvz2rhp33oibanfew6vk-lzjjwtd4gwmllk8b-wcceh-fc-20220923065203-ff-20240406181021-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    No &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38577791/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240405180803&amp;v=2.18.0.post9&#43;e462414">Exploring evolutionary trajectories in ovarian cancer patients by longitudinal analysis of ctDNA</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-05</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38577791-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240405180803-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: We demonstrate that tracing the temporal heterogeneity of ctDNA, even below exome scale resolution, deciphers evolutionary trajectories in ovarian cancer. Furthermore, we describe two evolutionary patterns that may help to identify relapse seeding clones for targeted &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38577801/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240405180803&amp;v=2.18.0.post9&#43;e462414">Navigating data standards in public health: A brief report from a data-standards meeting</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-05</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38577801-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240405180803-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    No &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38577820/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240405180803&amp;v=2.18.0.post9&#43;e462414">Antibodies against high-risk human papillomavirus proteins as markers for noncervical HPV-related cancers in a Black South African population, according to HIV status</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-05</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38577820-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240405180803-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Human papillomavirus (HPV) proteins may elicit antibody responses in the process toward HPV-related malignancy. However, HPV seroepidemiology in noncervical HPV-related cancers remains poorly understood, particularly in populations with a high prevalence of human immunodeficiency virus (HIV). Using a glutathione S-transferase-based multiplex serology assay, antibodies against E6, E7 and L1 proteins of HPV16 and HPV18 were measured in sera of 535 cases of noncervical HPV-related cancers (anal &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38577925/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240405180803&amp;v=2.18.0.post9&#43;e462414">[Retracted] Sulforaphane sensitizes human cholangiocarcinoma to cisplatin via the downregulation of anti‑apoptotic proteins</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-05</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38577925-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240405180803-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Following the publication of the above article and a corrigendum that was published in October 2023 to address the issue of misplaced control β‑actin western blots comparing between Figs. 3 and 4A (doi: 10.3892/or.2023.8646), an attentive reader drew to the authors' attention that the first author had apparently made additional unreported corrections to the revised version of Fig. 4 presented in the corrigendum. Although these image discrepancies did not alter the study&rsquo;s primary &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38578306/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240405180803&amp;v=2.18.0.post9&#43;e462414">Treatment response as surrogate to predict risk for disease progression in pediatric medulloblastoma with persistent MRI lesions after first-line treatment</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-05</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38578306-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240405180803-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSION: Overall response and extent of lesions can function as surrogate parameters to predict outcomes in pediatric MB patients with persistent lesions after first-line therapy. Especially in case of solitary persistent medulloblastoma MRI lesion, additional therapy was not beneficial. Therefore, treatment response, extent/kind of residual lesions and further diagnostic information needs consideration for indication of additional treatments for persisting &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38578306/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240406181050&amp;v=2.18.0.post9&#43;e462414">Treatment response as surrogate to predict risk for disease progression in pediatric medulloblastoma with persistent MRI lesions after first-line treatment</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-05</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38578306-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240406181050-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSION: Overall response and extent of lesions can function as surrogate parameters to predict outcomes in pediatric MB patients with persistent lesions after first-line therapy. Especially in case of solitary persistent medulloblastoma MRI lesion, additional therapy was not beneficial. Therefore, treatment response, extent/kind of residual lesions and further diagnostic information needs consideration for indication of additional treatments for persisting &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38578500/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240405180803&amp;v=2.18.0.post9&#43;e462414">Correction to: Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-05</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38578500-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240405180803-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    No &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38578500/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240406181050&amp;v=2.18.0.post9&#43;e462414">Correction to: Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-05</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38578500-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240406181050-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    No &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38578535/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240405180803&amp;v=2.18.0.post9&#43;e462414">&#34;The anxiety coming up to every scan-It destroyed me&#34;: A qualitative study of the lived experience of cytomegalovirus infection during pregnancy</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-05</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38578535-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240405180803-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSION: Serological diagnosis of maternal CMV infection during pregnancy can have severe and prolonged psychological impacts on parents, regardless of the pregnancy outcome. Improving healthcare professionals' knowledge and public awareness are essential before widespread serological screening can be responsibly introduced. Healthcare administrators that are considering implementing a prenatal screening program for secondary prevention of fetal CMV infection should pay attention to &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38578535/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240406181050&amp;v=2.18.0.post9&#43;e462414">&#34;The anxiety coming up to every scan-It destroyed me&#34;: A qualitative study of the lived experience of cytomegalovirus infection during pregnancy</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-05</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38578535-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240406181050-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSION: Serological diagnosis of maternal CMV infection during pregnancy can have severe and prolonged psychological impacts on parents, regardless of the pregnancy outcome. Improving healthcare professionals' knowledge and public awareness are essential before widespread serological screening can be responsibly introduced. Healthcare administrators that are considering implementing a prenatal screening program for secondary prevention of fetal CMV infection should pay attention to &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38578671/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240405180803&amp;v=2.18.0.post9&#43;e462414">Attributes, Methods, and Frameworks Used to Evaluate Wearables and Their Companion mHealth Apps: Scoping Review</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-05</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38578671-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240405180803-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: Our scoping review identified the types and categories of wearable devices and mHealth apps, their frequency of use in studies, and their implementation in the medical context. In addition, we examined the usability evaluation of these technologies: methods, attributes, and frameworks. Within the array of available wearables and mHealth apps, health care providers encounter the challenge of selecting devices and companion apps that are effective, user-friendly, and compatible &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38578671/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240406181050&amp;v=2.18.0.post9&#43;e462414">Attributes, Methods, and Frameworks Used to Evaluate Wearables and Their Companion mHealth Apps: Scoping Review</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-05</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38578671-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240406181050-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: Our scoping review identified the types and categories of wearable devices and mHealth apps, their frequency of use in studies, and their implementation in the medical context. In addition, we examined the usability evaluation of these technologies: methods, attributes, and frameworks. Within the array of available wearables and mHealth apps, health care providers encounter the challenge of selecting devices and companion apps that are effective, user-friendly, and compatible &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38578780/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240406181050&amp;v=2.18.0.post9&#43;e462414">Disruption of the mast cell carboxypeptidase A3 gene does not attenuate airway inflammation and hyperresponsiveness in two mouse models of asthma</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-05</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38578780-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240406181050-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Mast cells are effector cells known to contribute to allergic airway disease. When activated, mast cells release a broad spectrum of inflammatory mediators, including the mast cell-specific protease carboxypeptidase A3 (CPA3). The expression of CPA3 in the airway epithelium and lumen of asthma patients has been associated with a Th2-driven airway inflammation. However, the role of CPA3 in asthma is unclear and therefore, the aim of this study was to investigate the impact of CPA3 for &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38578871/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240406181050&amp;v=2.18.0.post9&#43;e462414">Cardiovascular-Kidney-Metabolic Syndrome: Association with Adverse Events After Major Noncardiac Surgery</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-05</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38578871-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240406181050-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSION: The newly defined CKM syndrome is associated with increased morbidity and mortality after non-cardiac surgery. Thus, cardiovascular, renal, and metabolic disorders should be regarded in mutual context in this &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38578888/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240406181050&amp;v=2.18.0.post9&#43;e462414">Clusterization of Behavioral and Psychological Symptoms of Dementia as Assessed by Neuropsychiatric Inventory: A Case Against the Use of Principal Component Analysis</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-05</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38578888-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240406181050-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: We recommend the thorough characterization of multivariate distributions before subjecting any dataset to Principal Component &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38579222/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240406181050&amp;v=2.18.0.post9&#43;e462414">Comment on &#34;Nuclear Excitation by Free Muon Capture&#34;</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-05</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38579222-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240406181050-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    No &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38579236/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240406181050&amp;v=2.18.0.post9&#43;e462414">Photoelectron Circular Dichroism in the Spin-Polarized Spectra of Chiral Molecules</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-05</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38579236-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240406181050-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    We studied strong-field multiphoton ionization of 1-iodo-2-methylbutane enantiomers with 395 nm circularly polarized laser pulses experimentally and theoretically. For randomly oriented molecules, we observe spin polarization up to about 15%, which is independent of the molecular enantiomer. Our experimental findings are explained theoretically as an intricate interplay between three contributions from HOMO, HOMO-1, and HOMO-2, which are formed of 5p-electrons of the iodine atom. For &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38579284/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=7603509&amp;fc=None&amp;ff=20240406181030&amp;v=2.18.0.post9&#43;e462414">Wiskott-Aldrich Syndrome: A study on 577 patients defining the genotype as a predictive biomarker for disease severity</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-05</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38579284-utm-source-curl-utm-medium-rss-utm-campaign-journals-utm-content-7603509-fc-none-ff-20240406181030-v-2-18-0-post9-e462414/">
    
    
    
    
    
      
    
    WAS is a multifaceted monogenic disorder with a broad disease spectrum and variable disease severity and a variety of treatment options including allogeneic hematopoietic stem cell transplantation (HSCT) and gene therapy (GT). No reliable biomarker exists to predict disease course and outcome for individual patients. A total of 577 patients with a WAS variant from 26 countries and a median follow-up of 8.9 years (0.3-71.1), totaling 6118 patient-years, were included in this &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38579285/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=7603509&amp;fc=None&amp;ff=20240406181030&amp;v=2.18.0.post9&#43;e462414">Bone marrow niches for hematopoietic stem cells: Lifespan dynamics and adaptation to acute stress</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-05</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38579285-utm-source-curl-utm-medium-rss-utm-campaign-journals-utm-content-7603509-fc-none-ff-20240406181030-v-2-18-0-post9-e462414/">
    
    
    
    
    
      
    
    Hematopoietic stem cells (HSCs) are instrumental for organismal survival as they are responsible for lifelong production of mature blood lineages in homeostasis and response to external stress. To fulfill their function, HSCs rely on reciprocal interactions with specialized tissue microenvironments, termed HSC niches. From embryonic development to advanced aging, HSCs transition through several hematopoietic organs where they are supported by distinct extrinsic cues. Here, we describe &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38579286/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=7603509&amp;fc=None&amp;ff=20240406181030&amp;v=2.18.0.post9&#43;e462414">Loss of stress sensor GADD45A promotes stem cell activity and ferroptosis resistance in LGR4/HOXA9-dependent AML</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-05</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38579286-utm-source-curl-utm-medium-rss-utm-campaign-journals-utm-content-7603509-fc-none-ff-20240406181030-v-2-18-0-post9-e462414/">
    
    
    
    
    
      
    
    The overall prognosis of acute myeloid leukemia (AML) remains dismal, largely due to the inability of current therapies to kill leukemia stem cells (LSCs) with intrinsic resistance. Loss of the stress sensor GADD45A is implicated in poor clinical outcomes but its role in LSCs and AML pathogenesis is unknown. Here we define GADD45A as a key downstream target of LGR4 oncogenic signaling and discover a regulatory role for GADD45A loss in promoting leukemia-initiating activity and &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38579288/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=7603509&amp;fc=None&amp;ff=20240406181030&amp;v=2.18.0.post9&#43;e462414">IL-18-secreting multi-antigen targeting CAR T-cells eliminate antigen-low myeloma in an immunocompetent mouse model</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-05</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38579288-utm-source-curl-utm-medium-rss-utm-campaign-journals-utm-content-7603509-fc-none-ff-20240406181030-v-2-18-0-post9-e462414/">
    
    
    
    
    
      
    
    Multiple myeloma is a plasma cell malignancy that is currently incurable with conventional therapies. Following the success of CD19-targeted chimeric antigen receptor (CAR) T-cells in leukemia and lymphoma, CAR T-cells targeting B-cell maturation antigen (BCMA) more recently demonstrated impressive activity in relapsed and refractory myeloma patients. However, BCMA-directed therapy can fail due to low expression of BCMA on myeloma cells, suggesting that novel approaches to better &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38579685/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240406181050&amp;v=2.18.0.post9&#43;e462414">NIBR-LTSi is a selective LATS kinase inhibitor activating YAP signaling and expanding tissue stem cells in vitro and in vivo</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-05</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38579685-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240406181050-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    The YAP/Hippo pathway is an organ growth and size regulation rheostat safeguarding multiple tissue stem cell compartments. LATS kinases phosphorylate and thereby inactivate YAP, thus representing a potential direct drug target for promoting tissue regeneration. Here, we report the identification and characterization of the selective small-molecule LATS kinase inhibitor NIBR-LTSi. NIBR-LTSi activates YAP signaling, shows good oral bioavailability, and expands organoids derived from several &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38579727/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240406181050&amp;v=2.18.0.post9&#43;e462414">Receptor transfer between immune cells by autoantibody-enhanced, CD32-driven trogocytosis is hijacked by HIV-1 to infect resting CD4 T cells</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-05</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38579727-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240406181050-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Immune cell phenotyping frequently detects lineage-unrelated receptors. Here, we report that surface receptors can be transferred from primary macrophages to CD4 T cells and identify the Fcγ receptor CD32 as driver and cargo of this trogocytotic transfer. Filamentous CD32^(+) nanoprotrusions deposit distinct plasma membrane patches onto target T cells. Transferred receptors confer cell migration and adhesion properties, and macrophage-derived membrane patches render resting CD4 T &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38579991/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240406181050&amp;v=2.18.0.post9&#43;e462414">Mst4, a novel cardiac STRIPAK complex associated kinase, regulates cardiomyocyte growth and survival and is upregulated in human cardiomyopathy</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-05</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38579991-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240406181050-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Myocardial failure is associated with adverse remodeling which includes apoptotic loss of cardiomyocytes, hypertrophy as well as alterations in cell-cell contacts. Striatin-interacting phosphatase and kinase (STRIPAK) complexes and their kinase Mst4 have been linked to the development of different diseases. The role and targets of Mst4 in cardiomyocytes have not been investigated, yet. Multi tissue immunoblot experiments show highly enriched Mst4-expression in rodent hearts. Analyses of &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38580340/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240406181050&amp;v=2.18.0.post9&#43;e462414">Incomplete sensorimotor paresis after upper abdominal surgery with TEA and spinal epidural lipomatosis: a case report</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-05</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38580340-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240406181050-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSION: So far, only two uncomplicated lumbar epidural catheter anesthesias have been described in patients who had a lumbar SEL. Epidural catheter anesthesia is a safe and effective method of pain control. But it is important to carefully identify and stratify patients with risk factors during the premedication visit. In patients who had kyphosis and thoracic localization of SEL, TEA may only be used after a risk-benefit &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38580343/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240406181050&amp;v=2.18.0.post9&#43;e462414">Impact of DMARD treatment and systemic inflammation on all-cause mortality in patients with rheumatoid arthritis and interstitial lung disease: a cohort study from the German RABBIT register</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-05</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38580343-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240406181050-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: Inflammatory biomarkers and absence of DMARD treatment were associated with increased risk of mortality in patients with RA-ILD. Non-TNFi bDMARDs may confer enhanced therapeutic benefits in patients with &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38581019/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240406181050&amp;v=2.18.0.post9&#43;e462414">Mesenchymal stromal cell chondrogenesis under ALK1/2/3-specific BMP inhibition: a revision of the prohypertrophic signalling network concept</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-05</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38581019-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240406181050-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: Overall, our data show that BMP-ALK1/2/3 inhibition cannot program mesenchymal stromal cells toward stable chondrogenesis. BMP-ALK1/2/3 signalling is no driver of hypertrophic MSC misdifferentiation and BMP receptor induction is not an adverse prohypertrophic side effect of TGF-β that leads to endochondral MSC misdifferentiation. Instead, the prohypertrophic network comprises misregulated PTHrP/hedgehog signalling and WNT activity, and a potential contribution &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38581034/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240406181050&amp;v=2.18.0.post9&#43;e462414">CNS tumors with PLAGL1-fusion: beyond ZFTA and YAP1 in the genetic spectrum of supratentorial ependymomas</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-05</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38581034-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240406181050-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    A novel methylation class, &ldquo;neuroepithelial tumor, with PLAGL1 fusion&rdquo; (NET-PLAGL1), has recently been described, based on epigenetic features, as a supratentorial pediatric brain tumor with recurrent histopathological features suggesting an ependymal differentiation. Because of the recent identification of this neoplastic entity, few histopathological, radiological and clinical data are available. Herein, we present a detailed series of nine cases of PLAGL1-fused supratentorial &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1251560221/O8hWkzHD6">Stanford斯坦福大学Matthew Porteus组在Cell Stem Cell发表了一项重要的HIV治愈研究。Matthew Porteus在医疗和科技领域非常有名，他是Stanford毕业的MD-PhD，现...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-05</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1251560221-o8hwkzhd6/">
    
    
    
    
    
      
    
    Stanford斯坦福大学Matthew Porteus组在Cell Stem Cell发表了一项重要的HIV治愈研究。Matthew Porteus在医疗和科技领域非常有名，他是Stanford毕业的MD-PhD，现在是Stanford MD-PhD项目（MSTP）副主任，并且是CRISPR Therapeutics的创建者之一。他的研究组发表的这项研究是一项重要的探索性HIV治愈研究，通过CRISPR-Cas9编辑造血干细胞（HSCs）CCR5来抵御R5和X4嗜性的HIV-1，使造血干细胞移植（HCT）后HIV无法感染移植物细胞。<!-- raw HTML omitted --><!-- raw HTML omitted -->目前全世界有5例HIV治愈病例全部是通过CCR5Δ32 HCT实现的（<!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;img style=&ldquo;width: 1rem;height: 1rem&rdquo; src=&ldquo;<a href="https://h5.sinaimg">https://h5.sinaimg</a>. &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1251560221/O8jDKix0j">Science发表了一篇评论文章引用了IHME Chris Murray数据指出，全球出生率持续下降，可能将在2030年提前出现人口增长拐点。按照传统的人口学理论（replacement fe...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-05</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1251560221-o8jdkix0j/">
    
    
    
    
    
      
    
    Science发表了一篇评论文章引用了IHME Chris Murray数据指出，全球出生率持续下降，可能将在2030年提前出现人口增长拐点。按照传统的人口学理论（replacement fertility rate）：平均每个妇女需要生育2.1个子女（TFR=2.1）才能抵消人口死亡率，使总人口稳定。TFR超过2.1则会出现人口增长；否则人口会下降。之前的很多研究预测，2056年之后，TFR将小于2.1，之后全人类会出现人口下降。但这篇文章引用的模型指出，2030年全人类可能就会出现TFR小于2.1的拐点，而TFR小于2.1后，随着老年人死亡，人类将在2060年出现全球人口绝对数量下降。&lt;img style=&quot;&quot; src=&ldquo;<a href="https://tvax1.sinaimg.cn/large/4a994b1dgy1hofzabmqpxj247n4dfe81.jpg%22">https://tvax1.sinaimg.cn/large/4a994b1dgy1hofzabmqpxj247n4dfe81.jpg&quot;</a> referrerpolicy=&ldquo;no-ref &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1251560221/O8jdNkax4">Fred Hutch的Larry Corey组（网页链接）在JCI发表了一篇HIV治愈研究论文，非常有意思。该研究直接用表达anti-PD-1 CAR-T试图治愈HIV，之所以觉得这项研究有意思...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-05</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1251560221-o8jdnkax4/">
    
    
    
    
    
      
    
    Fred Hutch的Larry Corey组（<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->网页链接<!-- raw HTML omitted --><!-- raw HTML omitted -->）在JCI发表了一篇HIV治愈研究论文，非常有意思。该研究直接用表达anti-PD-1 CAR-T试图治愈HIV，之所以觉得这项研究有意思，是因为PD-1+ Tfh细胞可能是HIV储藏库（&lt;a href=&ldquo;<a href="https://weibo.com/1251560221/4164">https://weibo.com/1251560221/4164</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/3825863518/O8i6D2NwB">必胜客的咖啡连水都算不上[怒][怒][怒][怒][怒][怒][怒][怒]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-05</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-3825863518-o8i6d2nwb/">
    
    
    
    
    
      
    
    必胜客的咖啡连水都算不上<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;img alt=&quot;[怒]&quot; &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/3825863518/O8i6n6uPk">说句实话，本淄博人今年应该能去吃一次淄博烧烤了[二哈]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-05</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-3825863518-o8i6n6upk/">
    
    
    
    
    
      
    
    说句实话，本淄博人今年应该能去吃一次淄博烧烤了<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->  &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5286768287/O8hCdmOHa">转发微博 - 转发 @山下美月教会:&amp;ensp;山下美月#山下美月手机博# 240404.2「材料」之后还开了会啥的哦—忙碌了之后经纪人说 你是不是还没吃饭就给了我饭团和猪肉...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-05</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5286768287-o8hcdmoha/">
    
    
    
    
    
      
    
    转发微博<!-- raw HTML omitted --><!-- raw HTML omitted --> - 转发 <!-- raw HTML omitted -->@山下美月教会<!-- raw HTML omitted -->: <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->山下美月<!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;a href=&ldquo;<a href="https://m.weibo.cn/search?containerid=231522type%3D1%26t%3D10%26q%3D%23%25E">https://m.weibo.cn/search?containerid=231522type%3D1%26t%3D10%26q%3D%23%E</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5286768287/O8kWtCLYN">摸摸肚肚 - 转发 @顶筆TEN使:&amp;ensp;久保史绪里via.seventeenjp_mag ins 顶筆TEN使的微博视频</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-05</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5286768287-o8kwtclyn/">
    
    
    
    
    
      
    
    摸摸肚肚<!-- raw HTML omitted --><!-- raw HTML omitted --> - 转发 <!-- raw HTML omitted -->@顶筆TEN使<!-- raw HTML omitted -->: <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->久保史绪里<!-- raw HTML omitted --><!-- raw HTML omitted -->via.seventeenjp_mag ins &lt;a href=&ldquo;<a href="https://video.weibo.com/show?fid=1034:5019757385023526%22">https://video.weibo.com/show?fid=1034:5019757385023526&quot;</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5286768287/O8n4fbwVU">转发微博 - 转发 @顶筆TEN使:&amp;ensp;久保史绪里天號星 院线发布 媒体图 [图片][图片][图片][图片][图片][图片][图片][图片][图片]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-05</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5286768287-o8n4fbwvu/">
    
    
    
    
    
      
    
    转发微博<!-- raw HTML omitted --><!-- raw HTML omitted --> - 转发 <!-- raw HTML omitted -->@顶筆TEN使<!-- raw HTML omitted -->: <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->久保史绪里<!-- raw HTML omitted --><!-- raw HTML omitted -->天號星 院线发布 媒体图 &lt;img style=&quot;&quot; src=&ldquo;<a href="https://tvax4.sinaimg.cn/large/006z6nxLgy1hog8rwl31lj30xc0m8t9k.jpg%22">https://tvax4.sinaimg.cn/large/006z6nxLgy1hog8rwl31lj30xc0m8t9k.jpg&quot;</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5286768287/O8n4hdpRq">转发微博 - 转发 @顶筆TEN使:&amp;ensp;久保史绪里via.Venue 101 官X 顶筆TEN使的微博视频</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-05</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5286768287-o8n4hdprq/">
    
    
    
    
    
      
    
    转发微博<!-- raw HTML omitted --><!-- raw HTML omitted --> - 转发 <!-- raw HTML omitted -->@顶筆TEN使<!-- raw HTML omitted -->: <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->久保史绪里<!-- raw HTML omitted --><!-- raw HTML omitted -->via.Venue 101 官X <!-- raw HTML omitted -->&lt;span &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5286768287/O8n4qEz9B">转发微博 - 转发 @顶筆TEN使:&amp;ensp;久保史绪里GEKI×CINE『天號星』 初日舞台相关视频</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-05</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5286768287-o8n4qez9b/">
    
    
    
    
    
      
    
    转发微博<!-- raw HTML omitted --><!-- raw HTML omitted --> - 转发 <!-- raw HTML omitted -->@顶筆TEN使<!-- raw HTML omitted -->: <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->久保史绪里<!-- raw HTML omitted --><!-- raw HTML omitted -->GEKI×CINE『天號星』 初日舞台相关视频 <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;video &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5286768287/O8n7eqJBY">今天（？其实是昨天了）也过得很开心！我煎的蛋姐姐包的锅贴配白象的火鸡面真的嘎嘎好吃今天打牌特别旺终于赢钱了！（不过拿去加油了[举车] [图片]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-05</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5286768287-o8n7eqjby/">
    
    
    
    
    
      
    
    今天（？其实是昨天了）也过得很开心！<!-- raw HTML omitted -->我煎的蛋姐姐包的锅贴配白象的火鸡面真的嘎嘎好吃<!-- raw HTML omitted -->今天打牌特别旺终于赢钱了！（不过拿去加油了<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5286768287/O8nf94yDX">这种事情不要啊[单身狗] - 转发 @山下美月教会:&amp;ensp;山下美月#山下美月手机博# 240405.4「晚安美月」和害羞鬼做了同样的表情眼睛真可怕明天有幸出演Venue101节...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-05</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5286768287-o8nf94ydx/">
    
    
    
    
    
      
    
    这种事情不要啊<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> - 转发 <!-- raw HTML omitted -->@山下美月教会<!-- raw HTML omitted -->: <!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;img style=&ldquo;width: 1rem;height: 1rem&rdquo; src=&ldquo;<a href="https://n.sinaimg.cn/photo/5213b46e/20180926/timeline_card_small_s">https://n.sinaimg.cn/photo/5213b46e/20180926/timeline_card_small_s</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5286768287/O8ngmydMR">yama桑什么时候来打扰一下我们哦噜耐头泥嘭</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-05</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5286768287-o8ngmydmr/">
    
    
    
    
    
      
    
    yama桑什么时候来打扰一下我们哦噜耐头泥嘭  &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5286768287/O8omo0c3e">一本同心词一本循循，真得劲</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-05</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5286768287-o8omo0c3e/">
    
    
    
    
    
      
    
    一本同心词一本循循，真得劲  &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5286768287/O8ooNov6R">月绪真甜</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-05</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5286768287-o8oonov6r/">
    
    
    
    
    
      
    
    月绪真甜  &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5402554084/O8hMJn0yf">恭喜咲月加入loveit家庭（每週五演出） [图片]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-05</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5402554084-o8hmjn0yf/">
    
    
    
    
    
      
    
    恭喜咲月加入loveit家庭（每週五演出） <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5402554084/O8iNKvyMb">转发微博 - 转发 @顶筆TEN使:&amp;ensp;久保史绪里via.seventeenjp_mag ins 顶筆TEN使的微博视频</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-05</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5402554084-o8inkvymb/">
    
    
    
    
    
      
    
    转发微博<!-- raw HTML omitted --><!-- raw HTML omitted --> - 转发 <!-- raw HTML omitted -->@顶筆TEN使<!-- raw HTML omitted -->: <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->久保史绪里<!-- raw HTML omitted --><!-- raw HTML omitted -->via.seventeenjp_mag ins &lt;a href=&ldquo;<a href="https://video.weibo.com/show?fid=1034:5019757385023526%22">https://video.weibo.com/show?fid=1034:5019757385023526&quot;</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5402554084/O8jlQdbDs">璃果出演「有點心機又何妨」！ [图片]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-05</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5402554084-o8jlqdbds/">
    
    
    
    
    
      
    
    璃果出演「有點心機又何妨」！ <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5402554084/O8jqboHGX">分享图片 [图片][图片]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-05</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5402554084-o8jqbohgx/">
    
    
    
    
    
      
    
    分享图片 <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5402554084/O8ncNoRhO">清麗 - 转发 @顶筆TEN使:&amp;ensp;久保史绪里天號星 院线发布 媒体图 [图片][图片][图片][图片][图片][图片][图片][图片][图片]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-05</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5402554084-o8ncnorho/">
    
    
    
    
    
      
    
    清麗<!-- raw HTML omitted --><!-- raw HTML omitted --> - 转发 <!-- raw HTML omitted -->@顶筆TEN使<!-- raw HTML omitted -->: <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->久保史绪里<!-- raw HTML omitted --><!-- raw HTML omitted -->天號星 院线发布 媒体图 &lt;img style=&quot;&quot; src=&ldquo;<a href="https://tvax4.sinaimg.cn/large/006z6nxLgy1hog8rwl31lj30xc0m8t9k.jpg%22">https://tvax4.sinaimg.cn/large/006z6nxLgy1hog8rwl31lj30xc0m8t9k.jpg&quot;</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5878312122/O8iLwlYvh">日本4月野榜（非官方）出炉，一力辽升至第一，广濑优一和关航太郎晋升前10，上野爱咲美进入前30#围棋#围棋 [图片]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-05</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5878312122-o8ilwlyvh/">
    
    
    
    
    
      
    
    日本4月野榜（非官方）出炉，一力辽升至第一，广濑优一和关航太郎晋升前10，上野爱咲美进入前30<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->#围棋#<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;span &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5878312122/O8jFjnKMn">严动虔这个斯蒂芬李行为太抽象了</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-05</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5878312122-o8jfjnkmn/">
    
    
    
    
    
      
    
    严动虔这个斯蒂芬李行为太抽象了  &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5878312122/O8jGwawXU">今年日本头衔战，执白胜率90%（9胜1负）另外，佩戴眼镜的棋手胜率100%#围棋#围棋</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-05</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5878312122-o8jgwawxu/">
    
    
    
    
    
      
    
    今年日本头衔战，执白胜率90%（9胜1负）<!-- raw HTML omitted --><!-- raw HTML omitted -->另外，佩戴眼镜的棋手胜率100%<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->#围棋#<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;span &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5878312122/O8jyXdKkr">严动虔坚持贯彻落实什么局面都最后一秒下棋，然后盘10&#43;变半目胜负#围棋#围棋</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-05</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5878312122-o8jyxdkkr/">
    
    
    
    
    
      
    
    严动虔坚持贯彻落实什么局面都最后一秒下棋，然后盘10+变半目胜负<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->#围棋#<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->围棋<!-- raw HTML omitted --><!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5878312122/O8k21dVIO">4月7日 下午2时 弈城围棋平台於之莹vs仲邑堇#围棋#围棋</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-05</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5878312122-o8k21dvio/">
    
    
    
    
    
      
    
    4月7日 下午2时 弈城围棋平台<!-- raw HTML omitted -->於之莹vs仲邑堇<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->#围棋#<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->围棋<!-- raw HTML omitted --><!-- raw HTML omitted -->  &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5878312122/O8mRY0n9I">发布了头条文章：《日本棋院成立和院社对抗战——日本围棋百大奠基人004》 #围棋# 围棋 日本棋院成立和院社对抗战——日本围棋百大奠基人004 [图片]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-05</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5878312122-o8mry0n9i/">
    
    
    
    
    
      
    
    发布了头条文章：《日本棋院成立和院社对抗战——日本围棋百大奠基人004》 <!-- raw HTML omitted --><!-- raw HTML omitted -->#围棋#<!-- raw HTML omitted --><!-- raw HTML omitted --> <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->围棋<!-- raw HTML omitted --><!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5878312122/O8munoAuM">发布了头条文章：《明知大学围棋系将被废除》 #围棋# 围棋 明知大学围棋系将被废除 [图片]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-05</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5878312122-o8munoaum/">
    
    
    
    
    
      
    
    发布了头条文章：《明知大学围棋系将被废除》 <!-- raw HTML omitted --><!-- raw HTML omitted -->#围棋#<!-- raw HTML omitted --><!-- raw HTML omitted --> <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->围棋<!-- raw HTML omitted --><!-- raw HTML omitted --> &lt;a href=&ldquo;<a href="https://weibo.com/">https://weibo.com/</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/6015489225/O8hYZ5Kpl">久保史绪里via.seventeenjp_mag ins 顶筆TEN使的微博视频</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-05</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-6015489225-o8hyz5kpl/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->久保史绪里<!-- raw HTML omitted --><!-- raw HTML omitted -->via.seventeenjp_mag ins <!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;img style=&ldquo;width: 1rem;height: 1rem&rdquo; src=&ldquo;<a href="https://h5.sinaimg.cn/upload/2015/0">https://h5.sinaimg.cn/upload/2015/0</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/6015489225/O8lMSskb8">久保史绪里天號星 院线发布 媒体图 [图片][图片][图片][图片][图片][图片][图片][图片][图片][图片][图片][图片][图片][图片][图片][图片][图片][图片]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-05</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-6015489225-o8lmsskb8/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->久保史绪里<!-- raw HTML omitted --><!-- raw HTML omitted -->天號星 院线发布 媒体图 <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;img style=&quot;&quot; src=&ldquo;<a href="https://tvax1.sinaimg.cn/large/006z6nxLgy1hog8rwx2zvj">https://tvax1.sinaimg.cn/large/006z6nxLgy1hog8rwx2zvj</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/6015489225/O8lNNcvkL">久保史绪里via.Venue 101 官X 顶筆TEN使的微博视频</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-05</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-6015489225-o8lnncvkl/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->久保史绪里<!-- raw HTML omitted --><!-- raw HTML omitted -->via.Venue 101 官X <!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;img style=&ldquo;width: 1rem;height: 1rem&rdquo; src=&ldquo;<a href="https://h5.sinaimg.cn/upload/2015/09/25/3/">https://h5.sinaimg.cn/upload/2015/09/25/3/</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/6015489225/O8lQi1KBr">久保史绪里GEKI×CINE『天號星』 初日舞台相关视频</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-05</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-6015489225-o8lqi1kbr/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->久保史绪里<!-- raw HTML omitted --><!-- raw HTML omitted -->GEKI×CINE『天號星』 初日舞台相关视频 <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;video controls=&ldquo;controls&rdquo; poster=&ldquo;<a href="https://tvax2.sinaimg.cn/orj480/006z6nxLgy1hog9agyizqj30xw0j20wh.jpg%22">https://tvax2.sinaimg.cn/orj480/006z6nxLgy1hog9agyizqj30xw0j20wh.jpg&quot;</a> style=&ldquo;width: &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://www.zhihu.com/question/651622023/answer/3455020839">张敬信回答了问题: r语言主成分分析怎么画图？</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-05</span>
  </div>
  <div class="summary">
    <a href="/post/www-zhihu-com-question-651622023-answer-3455020839/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted -->
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://www.zhihu.com/question/651719017/answer/3455023522">张敬信回答了问题: r 语言和统计学有什么联系？</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-05</span>
  </div>
  <div class="summary">
    <a href="/post/www-zhihu-com-question-651719017-answer-3455023522/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted -->
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://www.zhihu.com/question/651810365/answer/3455456418">张敬信回答了问题: 怎么用excel筛选出每年365天连续数据中每个月第一天对应的数据呢？</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-05</span>
  </div>
  <div class="summary">
    <a href="/post/www-zhihu-com-question-651810365-answer-3455456418/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted -->
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://zhuanlan.zhihu.com/p/690796427">量子位发表了文章: AIGC还是二刺猿会玩：捏娃社区爆火，有脑洞就能当同人大佬</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-05</span>
  </div>
  <div class="summary">
    <a href="/post/zhuanlan-zhihu-com-p-690796427/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted -->
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://zhuanlan.zhihu.com/p/690811646">量子位发表了文章: 谷歌更新Transformer架构，更节省计算资源！50%性能提升</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-05</span>
  </div>
  <div class="summary">
    <a href="/post/zhuanlan-zhihu-com-p-690811646/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted -->
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://zhuanlan.zhihu.com/p/690812325">量子位发表了文章: 最懂AI的诺奖经济学得主去世，大模型关键技术受他研究启发</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-05</span>
  </div>
  <div class="summary">
    <a href="/post/zhuanlan-zhihu-com-p-690812325/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted -->
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://zhuanlan.zhihu.com/p/690813153">量子位发表了文章: 10万美元训出Llama-2级大模型！全华人打造新型MoE，贾扬清SD前CEO围观</a></h1>
  <div class="date-author">
    
    <span class="date">2024-04-05</span>
  </div>
  <div class="summary">
    <a href="/post/zhuanlan-zhihu-com-p-690813153/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted -->
    </a>
  </div>
</section>

</main>
</div>

<script async src="//yihui.name/js/center-img.js"></script>

<footer>

<div class="footer">
  <ul class="menu">
    
    <li><a href="/"><span data-hover="Home">Home</span></a></li>
    
    <li><a href="/about/"><span data-hover="About">About</span></a></li>
    
    <li><a href="/archives/"><span data-hover="Archive">Archive</span></a></li>
    
    <li><a href="/contributor/"><span data-hover="Contributor">Contributor</span></a></li>
    
    <li><a href="/index.xml"><span data-hover="Subscribe">Subscribe</span></a></li>
    
  </ul>
  
  <div class="copyright">© <a href="https://rainoffallingstar.github.io">Fallingstar</a> 2023 | <a href="https://github.com/rainoffallingstar">Github</a></div>
  
</div>
</footer>







</body>
</html>

